Impact BioMedical, Inc.
As of Oct 22, 2026, Impact BioMedical is in Stage 4, the downtrend phase, now in week 2 (since Oct 13, 2026). It closed at $3.80, 61.5% below its 52-week high and below its 200-day average, which is falling.
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicro… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is IBO early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
IBO among Biotechnology350th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …350 | IBO | Stage 4 · wk 2 | 24 | −42.7% |
Impact BioMedical: quick answers
What stage is Impact BioMedical in?
As of Oct 22, 2026, Impact BioMedical (IBO) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 13, 2026 and is in week 2. What the four stages mean
Is Impact BioMedical in an uptrend?
No. Impact BioMedical is in a Stage 4 downtrend. It trades 40.2% below its 200-day average, which is falling.
How far is Impact BioMedical from its 52-week high?
Impact BioMedical closed at $3.80 on Oct 22, 2026, 61.5% below its 52-week high of $9.87. Its 52-week low is $2.68.
How has Impact BioMedical performed over the past year?
As of Oct 22, 2026, Impact BioMedical is down 48.7% over the past year and down 42.2% so far in 2026.
Which sector and industry is Impact BioMedical in?
Impact BioMedical is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use as health supplements and medications. Further, it is developing 3F (functional fragrance formulation), a formulation of botanical ingredients. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas. Impact BioMedical Inc. operates as a subsidiary of DSS BioHealth Security, Inc.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.